The trial enrolled non-cirrhotic patients with moderate baseline HBsAg (100 to 3,000 IU/mL) already on stable nucleotide analogue therapy. That selection matters because HBV-related deaths are driven almost entirely by cirrhosis and hepatocellular carcinoma, and those outcomes cluster in patients with higher antigen loads and advanced disease. The 19% result is real and independently replicated in over 1,800 patients, but whether bepirovirsen reduces the 1.1 million HBV deaths per year depends on trials in populations that weren't enrolled here.